Q2 2025 · 13F-HR
Euclidean Capital LLCholdings as filed
Filed 2025-08-14 · accession 0001012975-25-000445
$305.7M
Reported value
11
Positions
2025-06-30
Period end
The Brief · Euclidean Capital LLC · Q2 2025
AI · grounded in 13F
Euclidean Capital LLC established a new position in VEU valued at $144.03M. The fund also initiated a position in INDA for $135.03M. Other new additions include ORIC at $10.04M and FHTX at $7.40M. Total assets under management stand at $305.72M across 11 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 922042775 | VEU | VANGUARD INTL EQUITY INDEX F | $144.0M | 47.1% | 2,142,684 | Common | SOLE |
| 46429B598 | INDA | ISHARES TR | $135.0M | 44.2% | 2,425,144 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $10.0M | 3.28% | 989,410 | Common | SOLE |
| 344174107 | FHTX | FOGHORN THERAPEUTICS INC | $7.4M | 2.42% | 1,573,761 | Common | SOLE |
| 69353Y103 | PMVP | PMV PHARMACEUTICALS INC | $2.8M | 0.91% | 2,627,643 | Common | SOLE |
| 78462F103 | SPY | SPDR S&P 500 ETF TR | $2.5M | 0.83% | 4,104 | Common | SOLE |
| 014442107 | ALEC | ALECTOR INC | $1.8M | 0.60% | 1,307,858 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $784,002 | 0.26% | 87,696 | Common | SOLE |
| 75382E208 | RAPT | RAPT THERAPEUTICS INC | $657,872 | 0.22% | 82,234 | Common | SOLE |
| 87990A106 | TNYA | TENAYA THERAPEUTICS INC | $620,799 | 0.20% | 1,015,705 | Common | SOLE |
| 86889P117 | SRZNW | SURROZEN INC | $3,092 | 0.00% | 170,833 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.